Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera-Reference-Cited by-同舟云学术

Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera

Published:2021-09-03 Issue:5 Volume:16 Page:473-482
ISSN:1558-8211
Container-title:Current Hematologic Malignancy Reports
language:en
Short-container-title:Curr Hematol Malig Rep

Author:

How Joan,Hobbs Gabriela

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

https://link.springer.com/content/pdf/10.1007/s11899-021-00649-x.pdf

Reference80 articles.

1. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313–20.

2. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.

3. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

4. Network NCC. Myeloproliferative neoplasms (version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mpn_blocks.pdf. Accessed August 17, 2019.

5. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–7.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach;Advances in Clinical and Experimental Medicine;2024-04-29

2. Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice;eJHaem;2023-06-07

3. Novel therapeutic strategies for essential thrombocythemia/polycythemia vera;Blood Research;2023-04-30

4. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions;Annals of Hematology;2022-03-28